HK1215575A1 - 吡咯並吡啶或吡唑並吡啶衍生物 - Google Patents

吡咯並吡啶或吡唑並吡啶衍生物

Info

Publication number
HK1215575A1
HK1215575A1 HK16103515.2A HK16103515A HK1215575A1 HK 1215575 A1 HK1215575 A1 HK 1215575A1 HK 16103515 A HK16103515 A HK 16103515A HK 1215575 A1 HK1215575 A1 HK 1215575A1
Authority
HK
Hong Kong
Prior art keywords
pyrrolopyridine
pyrazolopyridine derivatives
pyrazolopyridine
derivatives
Prior art date
Application number
HK16103515.2A
Other languages
English (en)
Inventor
泰雷扎．瑪麗亞．巴拉爾
亞歷山大．弗洛爾
卡特里．格勒布科．茨賓登
伊曼紐爾．皮納德
托馬斯．里克曼斯
赫維．舍夫豪澤 é
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1215575A1 publication Critical patent/HK1215575A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
HK16103515.2A 2013-08-30 2016-03-24 吡咯並吡啶或吡唑並吡啶衍生物 HK1215575A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13182351 2013-08-30
PCT/EP2014/068114 WO2015028483A1 (en) 2013-08-30 2014-08-27 Pyrrolopyridine or pyrazolopyridine derivatives

Publications (1)

Publication Number Publication Date
HK1215575A1 true HK1215575A1 (zh) 2016-09-02

Family

ID=49036519

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16103515.2A HK1215575A1 (zh) 2013-08-30 2016-03-24 吡咯並吡啶或吡唑並吡啶衍生物

Country Status (13)

Country Link
US (1) US9932335B2 (zh)
EP (1) EP3039024A1 (zh)
JP (1) JP6434516B2 (zh)
KR (1) KR20160035068A (zh)
CN (2) CN108558867A (zh)
AR (1) AR099640A1 (zh)
BR (1) BR112015032637A2 (zh)
CA (1) CA2915952A1 (zh)
HK (1) HK1215575A1 (zh)
MX (1) MX2015017343A (zh)
RU (1) RU2016110483A (zh)
TW (1) TW201512197A (zh)
WO (1) WO2015028483A1 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201317363D0 (en) * 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
JP6517239B2 (ja) 2014-04-23 2019-05-22 武田薬品工業株式会社 アルツハイマー病治療のためのコリン作動性ムスカリンｍ１受容体ポジティブアロステリックモジュレーター活性としてのイソインドリン−１−オン誘導体
WO2015174534A1 (ja) 2014-05-16 2015-11-19 武田薬品工業株式会社 含窒素複素環化合物
NZ737892A (en) 2015-06-08 2018-09-28 Suven Life Sciences Ltd Muscarinic m1 receptor positive allosteric modulators
EP3347349B1 (en) 2015-09-10 2019-09-18 Suven Life Sciences Limited Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
KR20180110132A (ko) * 2016-02-16 2018-10-08 반더빌트유니버시티 무스카린성 아세틸콜린 수용체 m1의 양성 알로스테릭 조절제
CA3034775C (en) * 2016-09-02 2020-07-14 Suven Life Sciences Limited Muscarinic m1 receptor positive allosteric modulators
US10899759B2 (en) 2016-09-30 2021-01-26 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M1
WO2019000238A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000237A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000236A1 (en) * 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
KR102438588B1 (ko) * 2017-10-18 2022-08-31 수벤 라이프 사이언시스 리미티드 무스카린 m1 수용체 양성 알로스테릭 조절제로서 헤테로아릴 화합물
KR102406885B1 (ko) 2017-10-27 2022-06-08 수벤 라이프 사이언시스 리미티드 무스카린 m1 수용체 양성 알로스테릭 조절제로서 다환형 아미드
CN112543757A (zh) * 2018-06-15 2021-03-23 卡迪拉保健有限公司 对结核菌具有抗菌活性的缩合氮杂杂芳基化合物
WO2023082044A1 (zh) * 2021-11-09 2023-05-19 暨南大学 5-醛基杂环酰胺类化合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5461067A (en) * 1993-02-25 1995-10-24 Abbott Laboratories Retroviral protease inhibiting compounds
US8012992B2 (en) * 2008-06-30 2011-09-06 Allergan, Inc. Aza-indoles and related compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
WO2010019391A1 (en) * 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. N-heterocyclic m1 receptor positive allosteric modulators
EP2483275B1 (en) * 2009-10-01 2014-10-15 Merck Sharp & Dohme Corp. HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
SI2512243T1 (sl) * 2009-12-17 2016-07-29 Merck Sharp & Dohme Corp. Pozitivni alosterični modulatorji receptorja kinolin amid m1
EP2575454B1 (en) * 2010-05-28 2018-08-29 Merck Sharp & Dohme Corp. Naphthalene carboxamide m1 receptor positive allosteric modulators
US9012445B2 (en) * 2012-01-12 2015-04-21 Vanderbilt University Substituted 4-(1H-pyrazol-4-yl)benzyl analogues as positive allosteric modulators of mAChR M1 receptors
CN105636646B (zh) * 2013-07-17 2017-12-19 全球结核病药物研发联盟 氮杂吲哚化合物、其合成及其使用方法

Also Published As

Publication number Publication date
RU2016110483A (ru) 2017-10-04
US20160194321A1 (en) 2016-07-07
US9932335B2 (en) 2018-04-03
CN105358559A (zh) 2016-02-24
JP2016529268A (ja) 2016-09-23
AR099640A1 (es) 2016-08-10
BR112015032637A2 (pt) 2017-07-25
KR20160035068A (ko) 2016-03-30
CA2915952A1 (en) 2015-03-05
WO2015028483A1 (en) 2015-03-05
CN108558867A (zh) 2018-09-21
EP3039024A1 (en) 2016-07-06
MX2015017343A (es) 2016-04-06
TW201512197A (zh) 2015-04-01
JP6434516B2 (ja) 2018-12-05

Similar Documents

Publication Publication Date Title
HK1248138A1 (zh) 咪唑並吡啶化合物及其用途
HK1215575A1 (zh) 吡咯並吡啶或吡唑並吡啶衍生物
HK1215795A1 (zh) 鵝膏毒素衍生物
SG11201506100XA (en) Pyridazinone-amides derivatives
HK1223090A1 (zh) -氮雜吲哚衍生物
ZA201506747B (en) Imidazo pyridine compounds
ZA201601333B (en) Oxoquinazolinyl-butanamide derivatives
HRP20180473T1 (hr) 5-hidroksi-4-(trifluorometil) pirazolopiridin derivat
PL3022210T3 (pl) Nowy pochodne azabenzimidazolu
SG11201605189YA (en) Imidazopyrazinone derivatives
HK1222652A1 (zh) 取代的三唑並吡啶類
HK1208029A1 (zh) 咪唑並吡啶衍生物
HK1214244A1 (zh) 咪唑並吡啶衍生物
GB2517232B (en) Formulation
HK1209981A1 (zh) 配方
GB201312347D0 (en) Formulation
GB201306657D0 (en) Trestle